Albertsen, P. C., Hanley, J. A. & Fine, J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293, 2095–2101 (2005).
Wolters, T. et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J. Urol. 185, 121–125 (2011).
Van den Bergh, R. C. et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur. Urol. 55, 1–8 (2009).
Iremashvili, V. et al. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur. Urol. 62, 462–468 (2012).
Carter, H. B. et al. Early detection of prostate cancer: AUA guideline. J. Urol. 190, 419–426 (2013).
Adamy, A. et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J. Urol. 185, 477–482 (2011).
Ochiai, A., Troncoso, P., Chen, M. E., Lloreta, J. & Babaian, R. J. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J. Urol. 174, 2164–2168 (2005).
Parker, C., Muston, D., Melia, J., Moss, S. & Dearnaley, D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br. J. Cancer 94, 1361–1368 (2006).
Selvadurai, E. D. et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur. Urol. 64, 981–987 (2013).
Soloway, M. S. et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur. Urol. 58, 831–835 (2010).
Stamey, T. A. et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71, 933–938 (1993).
Tosoian, J. J. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J. Clin. Oncol. 29, 2185–2190 (2011).
Whitson, J. M. et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J. Urol. 185, 1656–1660 (2011).
Shaw, G. L. et al. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br. J. Cancer 110, 2405–2411 (2014).
Shah, N., Huebner, T., Ioffe, V. & Hum, R. Prostate biopsy characteristics: a comparison between pre- and post-United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012. Rev. Urol. 19, 25–31 (2017).
Draisma, G. et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 95, 868–878 (2003).
Moyer V. A. U. S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–34 (2012).
Mottet, N. et al. P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 71, 618–629 (2017).
R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2016).
Janssen, K. J. M. et al. Missing covariate data in medical research: to impute is better than to ignore. J. Clin. Epidemiol. 63, 721–727 (2010).
Delong, E. R., Delong, D. M. & Clarkepearson, D. I. Comparing the areas under 2 or more correlated receiver operating characteristic curves—a nonparametric approach. Biometrics 44, 837–845 (1988).
Klotz, L. Strengthening evidence for active surveillance for prostate cancer. Eur. Urol. 63, 108–110 (2013).
Klotz, L. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272–277(2015).
Ahmed, H. U. et al. PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).
Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. & Scardino, P. T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostatecancer. J. Natl. Cancer Inst. 90, 766–771 (1998).
D’Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969–974 (1998).